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Externally controlled on-demand release
of anti-HIV drug using magneto-electric
nanoparticles as carriers
Madhavan Nair1, Rakesh Guduru1, Ping Liang2, Jeongmin Hong1, Vidya Sagar1 & Sakhrat Khizroev1,2
Although highly active anti-retroviral therapy has resulted in remarkable decline in the
morbidity and mortality in AIDS patients, inadequately low delivery of anti-retroviral drugs
across the blood–brain barrier results in virus persistence. The capability of high-efﬁcacy-
targeted drug delivery and on-demand release remains a formidable task. Here we report an
in vitro study to demonstrate the on-demand release of azidothymidine 50-triphosphate, an
anti-human immunodeﬁciency virus drug, from 30nm CoFe2O4@BaTiO3 magneto-electric
nanoparticles by applying a low alternating current magnetic ﬁeld. Magneto-electric nano-
particles as ﬁeld-controlled drug carriers offer a unique capability of ﬁeld-triggered release
after crossing the blood–brain barrier. Owing to the intrinsic magnetoelectricity, these
nanoparticles can couple external magnetic ﬁelds with the electric forces in drug–carrier
bonds to enable remotely controlled delivery without exploiting heat. Functional and
structural integrity of the drug after the release was conﬁrmed in in vitro experiments with
human immunodeﬁciency virus-infected cells and through atomic force microscopy,
spectrophotometry, Fourier transform infrared and mass spectrometry studies.
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A
lthough highly active anti-retroviral therapy has resulted
in remarkable decline in the morbidity and mortality in
AIDS patients, zero or inadequately low delivery of anti-
retroviral drugs across the blood–brain barrier (BBB) and into the
brain and other tissue organs results in virus persistence1–3.
Hence, the elimination of human immunodeﬁciency virus-1
(HIV-1) reservoirs still remains a formidable task4,5. In recent
years, use of nanotechnology in medicine has shown exciting
prospect for the development of novel remotely controlled drug
delivery systems6,7. Besides magnetic nanoparticles (MNs)8–10,
other delivery systems rely on using thermally responsive
polymers, optically (ultraviolet (UV), visible wavelength and IR)
and acoustically activated nanostructures, liposomes, electro-
chemical processes and others. An extensive review of these and
other active triggering approaches was presented in the article by
Timko et al.11. The unique advantages of magnetically forced
triggering place this approach in a class of its own. In this case,
the speed of delivery is determined by the external magnetic ﬁeld.
For instance, as it is related to the delivery across the BBB, this
approach provides a way to deliver drugs sufﬁciently fast to avoid
their engulﬁng by the reticuloendothelial system. Nucleotide
reverse transcriptase inhibitor 30-azido-30-deoxythymidine-
50-triphosphate (AZTTP) is among the most challenging
anti-retroviral drugs to deliver across the BBB12,13. Previously
we have shown that MNs tagged with AZTTP transmigrated
across the BBB by the application of an external magnetic ﬁeld
without affecting the integrity of the BBB, and the transmigrated
AZTTP demonstrated signiﬁcant inhibition of HIV-1 p24 antigen
production in an in vitro infection model system compared
with the free AZTTP14. However, this MN-based delivery
suffers from the lack of certainty of drug release from the
carrier if and when the nano-carrier reaches the target. The
current presumptive mechanisms of drug delivery depend on
manually uncontrollable cellular phenomena such as exocytosis
of drug containing intracellular vesicle, intracellular Ca2þ
concentrations and pathology-speciﬁc responses (change in pH,
temperature, and so on)15. As a result, to obtain a relatively small
physiologic change and to ensure the release of the drug, the
binding force between the nano-carrier and the drug must be
maintained relatively weak. Consequently, more than 99% of the
drug/carriers are deposited in the liver, lungs and other lymphoid
organs before they reach the target. Therefore, an approach for
ﬁnely controlled and enhanced release of AZTTP in sufﬁcient
therapeutic levels in the brain or in other target organs is still
sought after, as it is critical for the complete eradication of HIV.
We present a study to demonstrate that dissipation-free,
energy-efﬁcient and low-ﬁeld on-demand drug release can be
achieved if the conventional MN carriers are replaced by
magneto-electric (ME) nanoparticles (MENs)16. ME materials
represent a relatively recently introduced class of multi-functional
nanostructures in which magnetic and electric ﬁelds can be
strongly coupled at body temperature17. Similar to the MNs,
MENs can be designed to have adequately high magnetic
moments and, therefore, also can be used for targeted delivery
by applying remote direct current (d.c.) magnetic ﬁelds. However,
owing to their non-zero magneto-electricity, unlike the traditional
MNs, MENs offer an additional feature that can enable a new
dissipation-free mechanism to force a high-efﬁcacy externally
controlled drug release process at the sub-cellular level using
remote low-energy d.c. and/or alternating current (a.c.) magnetic
ﬁelds.
An exaggerated illustration in Fig. 1 explains the concept of the
ﬁeld-triggered on-demand drug release from MENs. To simplify
the description, we use an example with a remote magnetic ﬁeld
in one speciﬁc direction, for example, along x axis, with respect to
the MEN drug nano-complex. The original (zero ﬁeld) ionic
bond, with charge Qionic of the nanoparticle, is schematically
shown in Fig. 1a. AZTTP molecules (typically interconnected in
chains) surround each MEN in a symmetric manner. As shown in
Fig. 1b, as a non-zero magnetic ﬁeld is applied, a non-zero electric
dipole moment is formed in the nanoparticle because of the non-
zero ME effect. For simplicity assuming an isotropic model, the
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Figure 1 | Illustration of the underlying physics of the a.c.-ﬁeld-triggered release. A simpliﬁed (one directional) illustration of the concept of on-demand
drug (AZTTP) release by MENs stimulated by a uniform a.c. magnetic ﬁeld in X direction. (a) At zero ﬁeld, only the ionic charge is present in the
MEN shell. (b) An additional dipole moment (proportional to the magnetic ﬁeld) breaks the original symmetry of the charge distribution in the shell.
(c) As the ﬁeld is increased above the threshold value (sionicBsME), the bond on one side is broken. (d,e) The ﬁeld is reversed to break the bond on the
opposite side of the nanoparticle. The red arrows show the electric dipole due to the ME effect. In practice, owing to the random conﬁgurations of
nanoformulations with respect to the ﬁeld, the effect is present along every central bond orientation.
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triggered dipole moment DP¼ aH, where a is the ﬁrst order ME
coefﬁcient and H is the magnetic ﬁeld. The amplitude of the
dipole charge surface density on each side of the nanoparticle
along the ﬁeld would be of the order of sMEB±aH, where
‘positive’ and ‘negative’ signs are applied to the opposite sides of
the dipole, respectively. The dipole moment breaks the original
symmetry of the charge in the MEN shell. Consequently, as
the magnitude of the magnetic ﬁeld is further increased above
the threshold value at which the dipole charge density on the
‘negative’ side becomes comparable to the positive ionic charge
density in the shell, sMEBQionic/pd2, that is, HthBQionic/pd2a,
where d is the diameter of the MEN, the bond in this direction
along the x axis will be broken while the opposite bond will be
further strengthened, as illustrated in Fig. 1c. By symmetry, to
break the bond in the opposite direction, the ﬁeld sequence
should be repeated in the reverse direction, as illustrated in
Fig. 1d,e. This simpliﬁed scenario doesn’t take into account the
randomness of the orientations of the nanoformulations. Ideally,
applying an a.c. magnetic ﬁeld that equivalently sweeps all bond
orientations will create a more uniform and efﬁcient bond-
breaking process over the surface of the nanoformulation, and
thus enhance the drug release efﬁcacy. In the next generation of
the technology, this goal can be achieved by using a spatially
rotating ﬁeld, which in turn can be accomplished, for example, by
using an array of coils that generate a.c. ﬁelds with non-zero
phase shifts with respect to each other.
In this study, we veriﬁed the hypothesis by demonstrating the
on-demand release of AZTTP from 30-nm CoFe2O4@BaTiO3
MENs by applying low a.c. and d.c. magnetic ﬁelds. We showed
that a 44Oe a.c. ﬁeld at 1,000Hz was sufﬁcient to trigger over
89% release. Further, to support the dissipation-free release
model, we could use a 66Oe d.c. ﬁeld to trigger a comparable
release level.
Results
Design of the experiment. We used atomic force microscopy
(AFM) in conjunction with UV spectrophotometry, Fourier
transform infrared (FTIR) analysis and mass spectroscopy to
directly trace the kinetics of the drug release process at different
stages of the release under the inﬂuence of remote d.c. and a.c.
magnetic ﬁelds. The three key stages included (i) the initial state
with separate MEN carriers and AZTTP molecules, (ii) the loaded
state in which MEN drug nanoformulations are formed and (iii)
the ﬁnal state after the a.c.-ﬁeld-forced separation of AZTTP and
MENs, that is, after the on-demand drug release. In vitro
experiments on HIV-infected human cells were conducted to
demonstrate the structural and functional integrity of AZTTP
after this physical release process. Below we present the key
results of this experimental study. The experiments are described
in more detail in the methods section.
Transmission electron microscopy study of MENs. In the
experiments described below, for the role of MENs we used
nanoparticles made of the popular core–shell composition
CoFe2O4@BaTiO3, in which the relatively high moment CoFe2O4
1-nm shell was used to enhance the ME coefﬁcient18. In general,
nanoparticles as small as 5 nm in diameter can be fabricated with
physical methods such as ion beam proximity lithography or
imprint lithography19. In this study, considering the novelty of
the approach, we focused on the main discovery of using MENs
for on-demand drug release rather than on the development of
scaling approaches. The default measurements were conducted
with 30-nm MENs. A typical transmission electron microscopy
image of the fabricated MENs, with clearly visible core–shell
structures, is shown in Fig. 2a. The composition of the MENs was
conﬁrmed through energy-dispersive spectroscopy, as shown in
Fig. 2b. The ME coefﬁcient for the nanoparticles was measured
via point I–V methods in the presence of a ﬁeld to be the order of
100V cm 1Oe 1, using an approach described in our previous
publication20.
Spectrophotometry study of the release. The goal of the ﬁrst
experiment was to measure the amount of the drug (AZTTP) at
different stages of the release process using the conventional
approach of spectrophotometry by measuring the UV light
absorption at the 267 nm maximum of the drug’s absorption
spectrum. We could bindB24% of the drug to the nanoparticles
by incubating AZTTP with the MENs in the Tris-EDTA (TE)
buffer (pH 7.4) for 3 h. The amount of the bound drug was
determined by estimating the concentration of AZTTP in the
unbound fraction (supernatant) of the incubation mixture by
spectrophotometry. To apply remote d.c. and a.c. magnetic ﬁelds,
we used a low-energy low-ﬁeld Helmholtz pair connected to a
function generator. The chart in Fig. 3 summarizes the key results
of this experiment, in which we measured the amount of the
unbound drug depending on the external ﬁeld strength and fre-
quency. It can be seen that application of a 44Oe ﬁeld at 1,000Hz
results in 89.3% of the drug being released, while application of a
d.c. ﬁeld of the same amplitude releases only 16.4% of the drug.
The data also conﬁrm that with higher frequency, a lower mag-
netic ﬁeld is needed to break the bonds because oscillation of the
bonds caused by a higher frequency ﬁeld facilitates the breaking
of the bonds. However, when a strong enough d.c. ﬁeld
(4B65Oe) is applied, the bond-breaking side of the drug chain
can gain enough momentum, causing the chain to break free
from the MEN shell even at zero frequency. To fully exploit the
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Figure 2 | Transmission electron microscopy (TEM) analysis of MENs. (a) ATEM image of MENs. The core–shell structure of a MEN is highlighted. Scale
bar, 100 nm. (b) An energy-dispersive spectroscopy (EDS) analysis of MENs.
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potential of the new controlled drug release nanotechnology, it is
important to conduct a more detailed pharmacokinetics study.
Pharmacokinetics study. In this experiment, MENs loaded
with AZTTP drug were exposed to an external magnetic ﬁeld at
different strengths (12, 44 and 66Oe) and frequencies (0, 100,
1,000Hz) for different treatment durations (1, 5, 10, 60 and
120min) in order to understand the release kinetics. Results are
summarized in the three-dimensional chart in Fig. 4. The quan-
titative values are also presented in Supplementary Table S1. For
every ﬁeld–frequency combination set we used a fresh solution
with AZTTP-loaded MENs.
FTIR analysis. The concept of the drug release by a remote
magnetic ﬁeld was conﬁrmed also through FTIR analysis, as
shown for the three key stages of the process kinetics in Fig. 5:
(top) free MENs and AZTTP before loading, (middle) loaded
state: MEN–AZTTP nanoformulations and (bottom) MENs after
the AZTTP release by a remote 44Oe ﬁeld at a 100Hz frequency.
Compared with the initial and ﬁnal unbound states, the loaded
state showed almost 30% weaker absorbance in general and a
transformed spectrum in the wavenumber region from 1,750 to
1,250 cm 1.
AFM study of the release kinetics. To observe the release process
at the molecular level, we conducted the following AFM mea-
surements. Figure 6 shows a sequence of AFM images that reﬂect
the following four stages of the release process: free (a) MEN and
(b) AZTTP chains, (c) loaded MEN–AZTTP nanoformulations,
and (d) MENs and (e) AZTTP after the release by a 44-Oe a.c.
ﬁeld at 1,000Hz. To obtain images c and d, the unloaded drug
was washed away with the supernatant. One can observe that the
MENs and AZTTP chains before the loading step and after the
release process look similar.
Field-controlled delivery and drug release by MENs. Translo-
cation experiments were performed on day 5 of BBB cell culture.
In order to achieve the translocation of AZTTP across the BBB,
AZTTP were loaded on MENs and subjected to an external
magnetic ﬁeld of 40Oe (to avoid any unwanted drug release at
higher ﬁelds) for 3 h and a gradient ofB22Oe cm 1 (to pull the
nanoparticles across the BBB) for 6 h of the incubation period. To
apply a ﬁeld normal to the BBB, the ﬁeld coils were placed below
the cell culture wells carrying the BBB model. Once the incuba-
tion was completed, the medium in the bottom chamber was
isolated and subjected to the a.c. magnetic ﬁeld (66Oe at 100Hz
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Figure 3 | Field strength and frequency dependence of the drug release.
Chart showing the release efﬁcacy of AZTTP drug bound to MENs by a
remote magnetic ﬁeld at different amplitudes and frequencies.
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Figure 5 | FTIR measurements. FTIR measurements for MEN–AZTTP
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loaded MENs and (iii) MENs after the release by the a.c. ﬁeld treatment
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ﬁeld for 5min) to increase the release percentage. After the ﬁeld
treatment, the MENs were isolated via a magnetic separation
technique. Once separated, the supernatant was measured for the
drug concentration via spectrophotometry. The results indicated
that B40% of the drug was translocated across the BBB as a
result of the process. These results are summarized in
Supplementary Fig. S1.
To further conﬁrm the structural and functional integrity of
the drug after the a.c. release process, we conducted: (i) a mass
spectrometry analysis of the drug before and after the release
(Supplementary Fig. S2 and Supplementary Table S2), (ii) an
in vitro experiment to study the p24 inhibition efﬁcacy of the
drug before and after the release (Supplementary Fig. S3). Finally,
to understand the cytotoxicity of MENs (CoFe2O4@BaTiO3), we
performed an XTT (sodium 2,3,-bis(2-methoxy-4-nitro-5-sulfo-
phenyl)-5-[(phenylamino)-carbonyl]-2H-tetrazolium inner salt)
assay on human astrocyte (HA) cells for neural cytotoxicity
and on human peripheral blood mononuclear cells (PBMCs)
for peripheral cytotoxicity. The results indicated no signiﬁcant
toxicity at a concentration of o50 mgml 1 (Supplementary
Table S3).
Discussion
The spectrophotometry experiment (Fig. 3) indicates the thresh-
old value, necessary for the ﬁeld to start the release of the AZTTP
drugs by the MENs, to be of the order of 10Oe, even though only
10% of the drug was released at such a low ﬁeld value. Using the
simpliﬁed expression we derived above for the release threshold
ﬁeld (HthBQionic/pd2a) and assuming the nanoparticle diameter
(d¼ 30 nm) and the ME coefﬁcient (a¼ 100V cm 1Oe 1), we
can evaluate the value for the effective charge, Qionic (responsible
for the ionic/covalent bond between the MEN and AZTTP
cluster), to be B10 17 C. The estimate seems reasonable and
indicates that approximately a few hundred electrons are involved
in the bond formation. Further, in agreement with the original
hypothesis, the experiment also proves that the a.c. ﬁeld provides
a substantially more enhanced release compared with that of the
d.c. ﬁeld. Indeed, at 12Oe ﬁeld amplitude, d.c. and a.c. (100Hz)
ﬁelds result in 1.9 and 10% released drug percentage, respectively.
To achieve almost full (89.3%) drug release, a ﬁeld of 44Oe at a
frequency of 1,000Hz is required. The effect of the a.c. ﬁeld
control is signiﬁcant in this case. For comparison, with a ﬁeld of
44Oe at the frequency of 100Hz, the released amount was 28.5%
while for the d.c. case at the same ﬁeld amplitude was only 16.4%.
The experiment indicates that such nanoformulations can be
directed to the targeted cells via a d.c. magnetic ﬁeld with a spatial
gradient while the drug can be effectively released on demand via
an external a.c. magnetic ﬁeld at 1,000Hz. Note that the highest
applied ﬁeld of 65Oe immediately saturated the system, resulting
in an almost full drug release even in the d.c. case. According to
our hypothesis, the latter can be explained by the magnetic-ﬁeld-
triggered large electric force that gave enough momentum to
break the bond. The results of the more detailed pharmaco-
kinetics study (Fig. 4) also indicate the presence of a certain
threshold ﬁeld that needs to be applied to trigger the release. The
threshold values at different frequencies reach their saturation
value in about 60min of the incubation process. Again, this
threshold ﬁeld exists even in the d.c. case (zero frequency) and
can be further reduced in the a.c. case by increasing the frequency
of an a.c. ﬁeld. To separate the d.c. and a.c. functions for drug
delivery and release, respectively, it is important to maintain the
amplitude of the ﬁeld below the saturation value, for example, at
44Oe. This separation of the d.c.- and a.c.-driven delivery and
release functions, respectively, was also conﬁrmed in the in vitro
experiment with a human BBB cell culture (Supplementary Fig.
S2). The FTIR results are in agreement with spectrophotometry
data (Fig. 5). Supporting the above release model, the initial state
(before drug loading) and the ﬁnal state (after the release) FTIR
spectra look similar, while the altered intermediate state reﬂects
the effect of binding between MENs and AZTTP molecules.
The AFM measurements (Fig. 6) directly illustrate the physical
difference between MEN–AZTTP nanoformulations and the free
MENs before loading and after releasing the drugs. In agreement
with the described spectrophotometry and FTIR measurements,
the AFM analysis also indicates that the MENs return to their
MEN and AZTTP
before binding
a d
c
b e
MEN–AZTTP
nanoformulations
MEN and AZTTP
after a.c. release
MEN AZTTP
Figure 6 | Atomic force microscopy study of the drug release kinetics. AFM images at different stages of the release process: (a) MENs and
(b) AZTTP chains before the loading (binding) step, (c) AZTTP–MEN nanoformulations after the loading process, (d) MENs and (e) AZTTP after the
drug release by a 44-Oe a.c. ﬁeld at 1,000Hz. Scale bar, 100 nm.
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original unbound state after the drug release triggered by a.c.
magnetic ﬁeld. In addition, AFM also proves the nanoscale nature
of the approach, with the potential to be applied at the sub-
cellular level. The in vitro experiment using human PBMCs
infected with HIV-1Ba-L proves the intact integrity of the drug
after the a.c.-triggered release (Supplementary Fig. S3).
The fundamental difference between MNs and MENs is due to
the presence in the latter of the quantum-mechanically caused
ME effect that enables intrinsic coupling between the magnetic
spin and the electric dipole. Consequently, energy-efﬁcient and
dissipation-free remote control of the intrinsic charge distribution
in the MENs (and consequently, control of the bonding force
between the MENs and the drug) can be enabled via application
of an external magnetic ﬁeld. Because of the intrinsic ME effect,
even if the drug is strongly bonded to the MEN carriers (as
required for high-efﬁcacy delivery), it can be fully released at the
target location via application of a local magnetic ﬁeld with a
strength above a certain threshold deﬁned by the ME effect. For
comparison, the drug release process using the conventional MNs
is not controlled at the same fundamental level but instead is
based on an irreversible energy dissipation process caused by an
external a.c. magnetic ﬁeld. In one MN implementation, super-
paramagnetic nanoparticles and drug molecules are incorporated
into temperature-sensitive synthetic polymers or other biomater-
ials that release the drug as the nanoparticles are heated under the
ﬁeld exposure21. In other implementations, superparamagnetic
nanoparticles can be coated with intermediate linkers (tailored to
speciﬁc load molecules), embedded in a ferro-gel, or directly
connected to the load molecules22,23. In either of these
conventional cases, the release mechanism with MNs is based
on extrinsic phenomena, that is, mechanical deformation and/or
heat dissipation that affects the release kinetics, that are triggered
by a relatively high frequency a.c. ﬁeld (in the range of hundreds
of kilohertz or above) and consume a substantial amount of
power (in the kilowatt range). On the contrary, the MEN-
triggered release process is achieved at the intrinsic level and does
not require any intermediate materials. It is dissipation free and
extremely energy efﬁcient. The release with MENs can be
triggered by an a.c. magnetic ﬁeld at a relatively low frequency
(below 100Hz) and even at a d.c. ﬁeld provided the ﬁeld strength
is above a certain threshold value, as described below in more
detail, with power consumption in the sub-watt range.
One can argue that MENs may also experience the potential
problem of having a relatively large fraction of the nanoparticles
(together or without the drug) trapped in the reticuloendothelial
system. One solution to this problem is to apply a ‘zig–zag’-
shaped time-varying ﬁeld proﬁle to move the nanoparticles
through the system. Then, besides the force along the main
delivery path, there is a signiﬁcant ‘jolting’ force normal to this
direction. This ‘jolting’ force ensures that the nanoparticles don’t
become trapped in the ﬁbres of the reticular connective tissue.
However, application of the strongly inertial ‘zig–zag’ force to the
conventional MNs can also result in a signiﬁcant loss of the drug.
On the contrary, with MENs, the physical bond between the drug
and the nanoparticle can be engineered to be adequately strong to
avoid any loss until a command to release is given via an external
ﬁeld.
As a ﬁnal remark, we would like to emphasize that although
MENs indeed have a unique advantage of serving in both roles, (i)
as regular MNs for drug delivery (via application of a d.c. remote
ﬁeld with a spatial gradient) and (ii) as drug release nanoscale
sites, their capability of an on-demand drug release by application
of a low remote magnetic ﬁeld in an extremely low frequency
range is unprecedented and therefore is a merit of its own (even
without exploiting the drug delivery feature). In general, this
physically controlled release method could be complementary to
any other drug delivery and tagging mechanism, whether it is
physical or chemical. Although AZTTP is used in the experiment,
the ability of on-demand drug release by a MEN nano-carrier
discovered in this study is also relevant to the treatment of
other diseases such as many CNS diseases, cancer and others,
where deep-tissue high-efﬁcacy drug delivery at the sub-cellular
level is key12.
Methods
Preparation of CoFe2O4-BaTiO3 core–shell MENs. CoFe2O4 nanoparticles were
prepared by hydrothermal method. In this method, 15ml of aqueous mixture of
0.058 g of Co(NO3)2.6H20, 0.16 g of Fe(NO3)3.9H20 and 0.2 g of poly-
vinylpyrrolidone is dissolved in 5ml of aqueous 0.9 g of sodium borohydride at
120 C for 12 h. Next, precursor solution of BaTiO3 was prepared by mixing 30ml
of aqueous 0.029 g of BaCO3 and 0.1 g of citric acid with 30ml of ethonalic solution
of 0.048ml titanium isopropoxide and 1 g of citric acid. CoFe2O4@BaTiO3 core–
shell MENs are prepared by dispersing 0.1 g of CoFe2O4 nanoparticles in the
precursor solution. The mixture was sonicated for 2 h. Well-dispersed mixture was
dried at 60 C for overnight while stirring continuously. Later, the mixture was
subjected to calcination at 780 C for 5 h. By reducing the cooling rate (controlled
by furnace CMF 1,100) from above 52 to below 14 Cmin 1, the average diameter
of MENs could be controlled from below 25 nm to over 100 nm, respectively, with
an adequate size distribution ofo30%. The particle size distribution was measured
by a Zetasizer Nano series via the standard dynamic light scattering approach. For
the 25-nm process (14 Cmin 1 cooling rate), the average size distribution ranged
from B19 to 31 nm.
Nanoformulations of AZTTP–MEN. Ten microlitres of AZTTP drug (10mM,
concentration) was added to the solution of 190 ml of TE buffer and 50 ml of
CoFe2O4BaTiO3 core–shell MENs (5mgml 1). Then, the solutions were incu-
bated for 2and 3 h, respectively. After the incubation, the solution was subjected to
the magnetic ﬁeld in order to precipitate the MENs (conjugated with AZTTP).
After the supernatant was isolated, its absorption was measured at 267 nm using
spectrophotometer Agilent Cary 100.
Spectro-photometric analysis of drug loading. Drug loading percentage¼
(absorbance of total amount of drug used—absorbance of drug used in supernatant
after incubating the drug and the MEN for a speciﬁc incubation time) 100%.
After 2-h incubation, the percentage of the drug in the supernatant was B89%,
which corresponded to B11% (100 89) of the drug bound to the MENs.
After 3-h incubation, the percentage of the drug in the supernatant was B76%,
which corresponded to B24% (100 76) of the drug bound to the MENs.
Drug release percentage: drug release percentage¼ (absorbance of supernatant
after magnetic ﬁeld treatment)/(absorbance of supernatant after incubating the
particles with drug) 100%. The absorbance signal was measured at the maximum
wavelength of 267 nm.
Magnetic ﬁeld treatment. To eliminate any potential residual unbounded drug,
after isolating the supernatant, the precipitate of the MENs conjugated with the
drug was washed once with the TE buffer. Then, the drug-conjugated particles
(AZTTP–MEN nanoformulations) were redispersed in 190 ml of the TE buffer, and
subjected to a magnetic ﬁeld of varying ﬁeld strength and frequency. Finally, the
solution was precipitated to pipette out the supernatant for further absorption
measurements.
Surface charge of MENs and AZTTP molecules. Because of the triphosphate
functional groups, in the chemical (covalent and/or ionic) bond between the MENs
and the AZTTP molecular cluster chains, the CoFe2O4-BaTiO3 MENs and the
AZTTP chains were positively and negatively charged, respectively.
Mass spectrometry analysis of AZTTP molecules and AZTTP bound to MEN.
To conﬁrm the integrity of AZTTP (C10H16N5O13P3; MW¼ 507) drug after the
a.c.-triggered release by MENs, we conducted a mass spectrometry analysis. The
analysis included a full scan qualitative identiﬁcation of the target analyte, a
chromatographic separation and an assessment of the presence of the drug in the
composite material (AZTTP–MEN nanoformulations) using multiple reaction
monitoring for appropriate transitions. Different mixes were contained in
Eppendorf vials. Using a 100-ml micropipette, 100 ml of each vial was transferred to
a new disposable polypropylene 96-well plate (part no. 5042-1386). The vials’
contents were subjected to a ﬂow injection analysis using electrospray ionization
with Jet Stream Technology in both positive and negative mode to assess the
presence of the AZTTP drug. The measurements were conducted with mass
spectrometer Agilent LC/MS Triple quadruple G6460 LC-QQQ. The ionization
conditions are presented in Supplementary Table S2. Supplementary Figure 2
shows the number of counts versus the mass-to-charge ratio for the three key
stages of the release process: (top) standard AZTTP, (middle) AZTTP bound to
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MENs, and (bottom) AZTTP and MEN after the a.c.-triggered release of the drug
load. The molecular weight of the AZTTP molecule is B507.
Preparation of samples for AFM and FTIR imaging. Ten microlitres of AZTTP
drug (10mM, concentration) was added to the solution of 190ml of the TE buffer
and 50ml of CoFe2O4-BaTiO3 core–shell MENs (5mgml 1). Then, the solution
was incubated for 3 h. After the incubation, one drop of solution was air dried on to
a pre-cleaned Si wafer. Once dried AFM imaging (topography and phase contrast)
was performed using Nanoscope IIIa Multimode.
For AZTTP the above solution without MENs was used and for MENs the above
solution without AZTTP was used.
For FTIR measurements, the sample preparation procedures were similar to the
one used for AFM.
In vitro BBB model. In vitro BBB model was prepared according to the procedure
described elsewhere24. The BBB model consisted of two compartments (upper and
lower), which were separated by the polyethylene terephthalate membrane of a
3.0-mm pore size (Becton Dickinson Labware, NJ, USA). In a 24-well cell culture
inserts, 2 105 human brain microvascular endothelial cells were grown to
conﬂuence on the upper side of the insert and the same amount of HAs were
grown on the underside. BBB cell culture was incubated for 4 days in order to reach
incubation conﬂuence at 37 C and 5% CO2. Transendothelial electrical resistance
was used to measure the intactness of the BBB. The average transendothelial
electrical resistance value for individual BBB was about 150–200 ohms cm 2,
which is consistent with formation of BBB.
p24 Assay to conﬁrm the integrity of AZTTP after ﬁeld-controlled release.
Normal PBMCs (10 106 cells) were infected with native HIV-1Ba-L (NIH AIDS
Research and Reference Reagent Programme catalogue no. 510) at a concentration
of 2 ngml 1 cells for 2 h, washed with phosphate-buffered saline (GIBCO-BRL,
Grand Island, NY) and returned to culture with and without fresh (new) or MEN-
released AZTTP at equimolar concentrations (200 nM). The culture supernatants
were quantitated for p24 antigen using a p24 ELISA kit (ZeptoMetrix, Buffalo, NY)
on the 5th day of infection. While the control sample showed the p24 con-
centration ofB33,050 pgml 1, the use of fresh and MEN-released AZTTP drugs
resulted in the concentration values of B1,300 and 1,800 pgml 1, respectively
(Supplementary Fig. S3). Therefore, considering the s.d. ofB300 pgml 1, the two
drug forms demonstrated equal p24 inhibition efﬁcacy.
In vitro cytotoxicity assay. To understand the in vitro cytotoxicity of MENs
(CoFe2O4@BaTiO3), we performed XTT assay according to the manufacturer’s
protocol (ATCC). XTT is a quantitative colorimetric assay, which is based on the
formation of an orange-coloured formazan dye by viable cells from the cleavage of
XTT tetrazolium salts. The assay was performed on HA cells for neuronal cyto-
toxicity and on PBMCs for peripheral cytotoxicity. In this assay, desired cells were
seeded in a 96-well cell culture plate at a 1 105 cells per well concentration and
incubated for 48 h. (The cell concentration and incubation time were standardized
by performing a pre-assay optimization protocol.) Following the incubation, the
cell culture medium was replaced by a medium containing MENs at a differential
concentration of 0–50 mgml 1. The cells were incubated in the MEN solution for
24 h. Once, the incubation period was completed the cells were washed with
phosphate-buffered saline buffer and later supplemented with a fresh medium. Cell
viability test was performed by XTT test kit as supplied by (ATCC) for 6 h. The
experiments that were performed in triplicate indicated no signiﬁcant toxicity at a
concentration of o50 mgml 1 (Supplementary Table S3).
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Corrigendum: Externally controlled on-demand
release of anti-HIV drug using magneto-electric
nanoparticles as carriers
Madhavan Nair, Rakesh Guduru, Ping Liang, Jeongmin Hong, Vidya Sagar & Sakhrat Khizroev
Nature Communications 4:1707 doi: 10.1038/ncomms2717 (2013); Published 16 April 2013; Updated 25 Oct 2013
This Article contains typographical errors in the second paragraph of the Results section and the ﬁrst paragraph of the Discussion
section. In each case the magneto-electric (ME) coefﬁcient of the nanoparticles was incorrectly cited in V cm 1Oe 1, whereas the
value should have been 100mVcm 1Oe 1.
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